Synthesis and Characterization of Bacterially Triggered System of Aceclofenac for Colon Targeting

Abstract

Aceclofenac has been considered as the potential treatment against ulcerative colitis. When administered orally aceclofenac are commonly absorbed by the upper gut. The potency of this effective chemical is enhanced by forming the specific drug delivery to the affected area. As all ulcerative colitis and crohn's disease occurs in the large bowel (or colon), which is beyond the site of absorption, it is necessary to modify aceclofenac to prevent it being absorbed in the upper gut. Many oral formulations are designed to maximize aceclofenac release in the colon where it acts topically on the colonic mucosa. So, the objective of this project was to produce a safe, targeted and effective azo prodrugs of aceclofenac with amino acids to treat the ulcerative colitis. The ordinary treatment of inflammatory bowel disease requires the frequent intake of anti-inflammatory drugs at higher doses, which causes the absorption of these drugs from small intestine, leading to significant adverse effects. Therefore, out of the need to overcome this formidable barrier of GIT, colonic drug delivery has evolved as the ideal drug delivery system for the topical treatment of local diseases of colon like Crohn’s disease or ulcerative colitis. To achieve successful colonic delivery, a drug needs to be protected from absorption and or the environment of upper GIT and then be abruptly released into proximal colon, which is considered as the optimum site for colon-targeted delivery of drug.